# Retatrutide UK approval timeline: MHRA authorisation, NICE appraisal and NHS access

> Projected UK regulatory pathway for retatrutide: FDA BLA in Q1 2027, possible MHRA authorisation around 2028, NICE appraisal and NHS access from 2029.

Canonical: https://yezz.co.uk/uk-approval-timeline · Last reviewed: 2026-09-11 · Author: Nick Johnson, Independent Prescription Pricing Analyst, Medstack Ltd

## Key facts
- The one firm date: Lilly plans to file its FDA Biologics License Application in Q1 2027 (stated 23 July 2026).
- Projection: MHRA marketing authorisation around 2028; private UK pharmacy supply from 2028 at the earliest.
- Projection: NICE appraisal from 2029 onwards; NHS availability 2029–2030+, phased to highest clinical need.
- The bottleneck: the TRIUMPH-Outcomes cardiovascular trial is not expected to complete until around 2029.
- There is no legal “early access” — any paid early-access or reservation offer is a scam.

---
Yezz is an independent UK information site run by Medstack Ltd. It sells nothing and provides general information, not medical advice.
Cite as: Nick Johnson. "Retatrutide UK approval timeline: MHRA authorisation, NICE appraisal and NHS access". Yezz, 2026-09-11. https://yezz.co.uk/uk-approval-timeline